Your path to success
ROME PHARMA GROUP (RPG) is a boutique pharmaceutical advisory firm focused on providing international business development services for pharmaceutical companies across the globe.
GENERIC AND 505(b)(2) PHARMACEUTICALS FROM
DEVELOPMENT TO DISTRIBUTION
About Us
Rome Pharma Group is your preferred Partner to build strategic relationships and create value along the entire pharmaceutical supply chain. We leverage decades of industry experience to help your organization capitalize in the current marketplace through meaningful partnerships, innovative ideas and tangible solutions.
Leadership
Rome Pharma Group is led by Jonathan Rome, an executive and entrepreneur with more than 40 years of experience in the pharmaceutical industry.
Alongside the founding of Rome Pharma Group in 2012, Jonathan co-founded and served as CEO of Patagonia Pharmaceuticals, a specialty pharmaceutical company focused on developing innovative prescription therapies for rare dermatological diseases. After a successful Phase 2 study, Patagonia sold a majority of its assets to Timber Pharmaceuticals (NYSE: TMBR) in 2019.
Jonathan served as Chairman of the Board at Crown Laboratories, Inc., a fully integrated specialty pharmaceutical company focused on topical dermatological products. Jonathan's leadership in this role helped successfully facilitate the sale of a majority stake to Hildred Capital Partners in 2017.
In 2000, Jonathan started ThePharmaNetwork (TPN), LLC, an API procurement and product development company with offices in New Jersey, Connecticut, Shanghai, and Rome. Ascend Laboratories, LLC, a wholly owned subsidiary of TPN, was started in 2003 as a generic pharmaceutical development and Sales & Marketing company. Ascend became the 3rd fastest growing generic drug company in 2011 (IMS Health). In 2012, TPN and Ascend were acquired by one of the largest Indian pharmaceutical companies, Alkem Laboratories, Ltd.
In 1989, Jonathan joined Zenith Laboratories, Inc. as the Executive Vice President of the team assembled to bring the Company out of bankruptcy. In less than 5 years, Zenith grew from $28 million in sales to over $250 million, leading to the Company's acquisition by Ivax Pharmaceuticals, In.c for $600 million in 1994.
Jonathan's extensive experience in nearly all aspects of the pharmaceutical industry help him lead the team at Rome Pharma Group to provide unparalleled services to clients across the globe.
Services
Strategy
Engage with our experts to conduct a thorough strategic analysis and develop a tailor-made plan to ensure your goals are achieved.
Business Development
Proven experience identifying and executing strategic opportunities to cultivate partnerships, enter new markets, reduce costs, and develop new business targets.
Portfolio Optimization
Enhance your product portfolio with our exclusive in-licensing, out-licensing, acquisition and divestiture opportunities.
Global Engagement
Extensive international network and curated partnerships with pharmaceutical companies across North America, Europe, and Asia.
Our
Clients
Rome Pharma Group is committed to delivering world-class services to our customers.
We work with pharmaceutical companies of all sizes, from small and mid-sized businesses to Fortune 500 and entities listed on foreign public markets.
